for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Samsung Biologics Co Ltd

207940.KS

Latest Trade

719,000.00KRW

Change

-29,000.00(-3.88%)

Volume

139,386

Today's Range

713,000.00

 - 

739,000.00

52 Week Range

352,000.00

 - 

883,000.00

As of on the Korea Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
748,000.00
Open
735,000.00
Volume
139,386
3M AVG Volume
3.07
Today's High
739,000.00
Today's Low
713,000.00
52 Week High
883,000.00
52 Week Low
352,000.00
Shares Out (MIL)
66.17
Market Cap (MIL)
47,572,640.00
Forward P/E
124.67
Dividend (Yield %)
--

Next Event

Samsung Biologics Co Ltd Annual Shareholders Meeting

Latest Developments

More

Samsung BioLogics Q4 Operating Profit 93 Billion Won, Down 13% From Year Earlier

Samsung Biologics' Strategic Business Operations Continue To Support Strong Third Quarter Earnings

Samsung Biologics Says Co & AstraZeneca Forge Strategic Manufacturing Partnership For Global Supply

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Samsung Biologics Co Ltd

Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.

Industry

Biotechnology & Drugs

Contact Info

300, Songdo bio-daero, Yeonsu-gu

21987

South Korea

+82.32.4553114

https://www.samsungbiologics.com/

Executive Leadership

John Chongbo Rim

President, Chief Executive Officer

Dongjoong Kim

Chief Financial Officer, Director

Kyu Sung Lee

Executive Vice President

Gwang Hun Yun

Executive Vice President

In Gyu Kim

Senior Vice President

Key Stats

1.86 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, KRW)

2018

0.5K

2019

0.7K

2020

1.2K

2021(E)

1.4K
EPS (KRW)

2018

3,387.000

2019

3,067.000

2021(E)

5,767.395
Price To Earnings (TTM)
197.42
Price To Sales (TTM)
40.84
Price To Book (MRQ)
10.34
Price To Cash Flow (TTM)
123.39
Total Debt To Equity (MRQ)
17.07
LT Debt To Equity (MRQ)
12.77
Return on Investment (TTM)
4.36
Return on Equity (TTM)
3.91

Latest News

Latest News

Samsung BioLogics says mass producing Eli Lilly's COVID-19 treatment

Samsung BioLogics Co Ltd on Tuesday said it is mass-producing a COVID-19 antibody treatment developed by Eli Lilly and Co, as the United States began distributing the drug last week after emergency-use approval.

BRIEF-Samsung BioLogics says wins 381 bln won order to make biopharmaceuticals for European firm

* SAMSUNG BIOLOGICS: WINS 381 BILLION WON ORDER TO MANUFACTURE BIOPHARMACEUTICALS FOR EUROPEAN FIRM Further company coverage: (Reporting by Joyce Lee)

South Korea's Samsung Biologics signs $231 million supply deal with GSK

South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years.

BRIEF-Samsung BioLogics says wins 442 bln won order to produce biopharma drug

* SAMSUNG BIOLOGICS: WINS 442 BILLION WON ORDER FOR CONTRACT PRODUCTION OF BIOPHARMA PRODUCT FROM U.S. FIRM Further company coverage: (Reporting by Joyce Lee)

BRIEF-Samsung Biologics & STCube Enter Development & Manufacturing Agreement​ For ‍STT-003 Antibody​

* SAMSUNG BIOLOGICS CO LTD - CO & STCUBE ANNOUNCED A STRATEGIC DEVELOPMENT AND MANUFACTURING SERVICE AGREEMENT FOR STT-003 ANTIBODY

BRIEF-Samsung Biologics Co Ltd Confirms 'No Impact' Of COVID-19 With Business Continuity Plan In Effect

* SAMSUNG BIOLOGICS CO LTD - CONFIRMS 'NO IMPACT' OF COVID-19 WITH BUSINESS CONTINUITY PLAN IN EFFECT Source text for Eikon: Further company coverage:

South Korea watchdog says to appeal court move to suspend Samsung BioLogics' sanctions

South Korea's top financial regulator, the Financial Services Commission (FSC), said on Tuesday it will file an appeal against a court decision to suspend sanctions on Samsung BioLogics Co Ltd.

South Korean court suspends regulator's disciplinary action against Samsung BioLogics

A South Korean court has suspended the financial regulator's disciplinary action against Samsung BioLogics Co Ltd <207940.KS> for allegedly breaching accounting rules, an official at the Seoul Administrative Court said on Tuesday.

S.Korean court suspends regulator's disciplinary action against Samsung BioLogics

A South Korean court has suspended the financial regulator's disciplinary action against Samsung BioLogics Co Ltd over breach of accounting rules, an official at the Seoul Administrative Court said on Tuesday.

South Korean prosecutors raid Samsung BioLogics' office in accounting probe

Samsung BioLogics Co Ltd's <207940.KS> on Thursday said its head office has been raided by South Korean prosecutors as part of a criminal probe into alleged accounting fraud.

S.Korean prosecutors raid Samsung Biologics' office in accounting probe

South Korean prosecutors on Thursday raided Samsung Biologics Co Ltd's head office outside of Seoul as part of a probe into alleged accounting fraud, the company said.

UPDATE 1-Samsung BioLogics shares to remain listed, resume trade on Dec. 11

South Korea's main stock exchange has decided Samsung BioLogics Co Ltd is qualified to continue trading on the exchange and that the company's shares will resume trading on Tuesday, the bourse said on Monday.

Samsung BioLogics shares to remain listed, resume trade on Dec. 11

South Korea's main stock exchange has decided Samsung BioLogics Co Ltd is qualified to continue trading on the exchange and that the company's shares will resume trading on Tuesday, the bourse said on Monday.

Samsung BioLogics files administrative lawsuit against regulator

Samsung BioLogics Co Ltd <207940.KS> said on Wednesday it had filed an administrative lawsuit against South Korea's financial regulator over the watchdog's recent ruling on accounting violations.

Samsung BioLogics' listing under review after regulator says it breached accounting rules

South Korea's top financial regulator said Samsung BioLogics Co Ltd <207940.KS> had intentionally breached accounting rules ahead of its 2016 listing, leading to a suspension in trading of the biotech firm's shares and a review of its listing status.

S.Korea regulator says Samsung BioLogics intentionally breached accounting rules

South Korea's top financial regulator on Wednesday said it found Samsung BioLogics Co Ltd intentionally breached accounting rules in inflating the company's value ahead of its 2016 stock exchange listing.

Samsung BioLogics shares plunge over accounting concerns

Shares in Samsung BioLogics Co Ltd <207940.KS> plunged on Monday amid concerns about its accounting practices ahead of a meeting of regulators this week to review whether it has violated rules which could lead to its delisting.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up